The drug development industry is historically characterized by high costs, lengthy timelines, and significant risk. Statistics show that in traditional scenarios, bringing a novel drug from discovery to market takes an average of 10-15 years and costs over $2 billion. How can this challenge be overcome? SIMCERE PHARMA (ASX: 02096) has chosen to leverage world-renowned artificial intelligence technology to restructure its drug development processes, rapidly expand its pipeline portfolio, and accelerate the fundamental transformation of its innovative drug R&D and commercialization model.
On July 10th, SIMCERE PHARMA announced a global drug discovery and development collaboration agreement with the leading AI platform company, Schrödinger. The agreement will see the two parties focus on unmet clinical needs. They will integrate SIMCERE PHARMA's R&D expertise and clinical development capabilities in neuroscience, oncology, autoimmune diseases, and anti-infectives with Schrödinger's globally leading physics-based and AI-driven drug design platform to jointly advance the discovery and development of innovative medicines.
Leveraging Top-Tier AI to Accelerate High-Value Asset Realization
For a pharmaceutical company committed to sustained commercial scale and innovation delivery, the growth of its investment value is closely tied to its ability to translate R&D achievements. Relying on a scarce AI technology platform to efficiently realize the value of high-value innovative assets is a key reason for SIMCERE PHARMA's increased investment in AI-driven drug discovery and its strategic partnership with Schrödinger.
This collaboration signals SIMCERE PHARMA's intent to enrich its self-developed innovative drug pipeline and speed up the conversion of valuable assets. In recent years, the company has undergone a rapid transformation, emerging as a domestic innovator with strong R&D capabilities, a focus on delivering global clinical value, and a leading pace in pipeline advancement. Data indicates that by 2025, SIMCERE PHARMA already had 10 marketed innovative drugs and a pipeline of over 60 investigational candidates. Driven by robust innovation and approximately 9 billion RMB in R&D investment over the past five years, innovative drug revenue accounted for 81.5% of its total in 2025.
Sustained R&D investment has not only driven the continuous realization of its innovative pipeline but also propelled "out-licensing" into a new growth engine. In 2025, the company licensed three early-stage oncology research products to international giants AbbVie and Ipsen. In January of this year, it licensed the overseas rights for its autoimmune bispecific antibody SIM0709 to Boehringer Ingelheim, in a deal with a potential value of up to 1.058 billion euros. The company has now completed five out-licensing deals with a total potential value exceeding $4.6 billion. This "R&D-license-reinvest" model is becoming an important component of its profit structure.
Against this backdrop, the partnership with Schrödinger not only demonstrates that the value of SIMCERE PHARMA's multi-therapeutic area innovation has received strong validation from a global AI drug discovery leader but also enables the deep integration of AI into its R&D system. This will continuously improve the input-output efficiency of innovation, further unleashing the company's R&D and commercial strengths in neuroscience, oncology, autoimmune diseases, and anti-infectives. While addressing vast unmet medical needs, this provides powerful momentum for the company's future growth.
Innovation Strength Gains Recognition from Leading AI Platform
By 2026, the global AI drug discovery industry is formally transitioning from a "capital narrative" to a phase of scaled implementation. In this industry evolution, Schrödinger has secured a unique and scarce position in the global AI drug discovery field, thanks to its profound foundation in computational chemistry and advanced machine learning algorithms.
Schrödinger has long focused on using its AI-powered computational platform to accelerate drug development and materials design. By deeply integrating physics-based computational techniques with AI, it has built a powerful platform that serves both its internal drug discovery efforts and empowers pharmaceutical companies and academic institutions worldwide. Based on physics and chemical analysis, this platform enables precise model predictions, leading to the discovery of higher-quality molecules at lower cost and greater speed. The computational platform can evaluate billions of compound molecules weekly. Furthermore, it allows for iterative cycles on compounds before synthesis and testing, enabling comprehensive evaluation and optimization.
Currently, Schrödinger collaborates extensively with leading global pharmaceutical companies, including AstraZeneca and Bayer. Its AI drug discovery platform is used by numerous biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. It is evident that Schrödinger possesses deep scientific expertise and extensive development experience in the global AI drug discovery arena. Its decision to partner with SIMCERE PHARMA clearly reflects recognition of the latter's proven R&D accumulation and clinical development capabilities in neuroscience, oncology, autoimmune diseases, and anti-infectives. This represents high-level endorsement from an international AI leader of the company's innovative R&D strength.
For SIMCERE PHARMA, this collaboration with Schrödinger is not its first foray into AI drug discovery. As early as 2020, the company collaborated with AlphaMol, focusing on virtual screening for lead compounds in oncology, neurology, and autoimmune disease targets, utilizing AI machine learning models to establish target-specific screening systems. Subsequently, to further explore the potential of AI technology in early-stage innovative drug R&D, SIMCERE PHARMA actively explored private AI deployment and built applications for various scenarios, establishing an "AI+ Department" to accelerate AI application work. The collaboration with Schrödinger is evidently a crucial part of SIMCERE PHARMA's long-term "AI+" strategic layout.
Partnering with Schrödinger means the company gains significant support from its scarce AI platform technology for both drug discovery and subsequent commercial development. This collaboration represents a deep integration and complementary pairing between the technological efficiency of an AI platform and robust innovative drug R&D capabilities.
Concluding Perspective
At the inflection point of scaled implementation for AI drug discovery, SIMCERE PHARMA's collaborative exploration with a global AI technology giant provides valuable experience for the industry. Its potential success lies not only in technological cooperation but also in its synergistic R&D model combining "leading AI platform + expert experience" – where Schrödinger's AI platform handles massive data screening and preliminary design, and SIMCERE PHARMA's scientists focus on key decision-making and optimization validation. The combination unleashes multiplied innovation efficacy.
Driven by policy, technology, and capital, AI drug discovery is moving from concept to large-scale implementation. The deep collaboration between SIMCERE PHARMA and Schrödinger not only promises more efficient treatment options for patients but also offers an important reference for the upgrade of China's pharmaceutical industry. It is foreseeable that with the continuous evolution of AI technology, the intelligent wave will sweep through every corner of the innovative drug industry, further accelerating the development of novel therapies and allowing patients worldwide to benefit from the immense dividends brought by AI technology.